Welcoming two new members to our Strategic Innovation Advisory Board

Welcoming two new members to our Strategic Innovation Advisory Board

The Max Foundation is excited to include Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD as the newest Strategic Innovation Advisory Board member.

Graciela Mabel Woloj Rothstein is an experienced leader with a demonstrated history of working within the pharmaceuticals industry. Rothstein brings her expertise in the fields of Oncology, Good Clinical Practice (GCP), Pharmacovigilance, Clinical Trial Management System (CTMS), and Biotechnology.

Dr. Mikkel Z Oestergaard is Director of Health Technology Assessment (HTA) Statistics within the Department of Biostatistics and Research Decision Sciences at Merck/MSD and is based in Zurich, Switzerland. He has 16 years of professional experience and more than 40 peer-reviewed scientific publications in the areas of clinical drug development, health statistics and evidence-generation for public health impact. Dr. Oestergaard previously worked at the World Health Organization (WHO) headquarter before subsequently moving to the pharmaceutical industry. At the WHO he focused on evaluation of the global burden of disease, and co-founded WHO’s Global Initiative on Genomics for Public Health.

We are eager to learn from Rothstein and Oestergaard’s knowledge and experience in the pharmaceutical industry, in order to bring more access to treatment for patients worldwide. Join us in welcoming Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD to our advisory board!

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Announces Multi-Stakeholder Collaboration to Improve Outcomes for People Living with Advanced Breast Cancer in Low-Resource Countries

    Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid and Novartis AG are joining and committing resources to a unique collaboration Breast cancer is….

  • The Max Foundation Releases Video from Global Experience

    The Max Foundation Releases Video from Global Experience

    Watch The Max Foundation’s video from Max Global Experience Uganda. The Max Global Experience Uganda was a fundraising and engagement opportunity for patient leaders, industry partners, and Max team members to come together to expand access to cancer treatment in Africa. The global experience included an all-day symposium, a visit to the Uganda Cancer Institute, and a “last mile” walk along the Nile in solidarity with patients across Africa.

  • New study confirms an excellent survival rate of cancer patients in a medication donation program

    New study confirms an excellent survival rate of cancer patients in a medication donation program

    A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.